{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 40 of 122', '5.5.1', 'Safety Follow-Up for Subjects With GI Adverse Events of Interest', 'For subjects who had GI adverse events of interest (ie, with prolonged dose interruption or', 'that result in or are ongoing at early discontinuation; Section 8.5.6.2), parents/caregivers and', 'subjects aged > 8 years will complete the Pediatric Eosinophilic Esophagitis Symptom', 'Scores version 2.0 (PEESS v2.0) questionnaire while the subject is symptomatic, at early', 'discontinuation or study exit, and monthly for 6 months.', 'In addition, subjects who discontinue early due to GI adverse events will return to the study', 'site monthly for at least 6 months; telephone follow-up by medically qualified personnel may', 'be appropriate in the absence of symptoms, at the discretion of the investigator.', 'A gastroenterologist referral should be initiated for subjects with GI adverse events persisting', '> 6 weeks after early treatment discontinuation, and for subjects unable to discontinue using', 'therapies initiated for GI symptoms (eg, H1 or H2 histamine blockers, proton pump', 'inhibitors) by 12 weeks after early treatment discontinuation. Gastroenterologist visits, test', 'results, and endoscopy and endoscopic biopsy results (if applicable) will be documented in', \"the subject's source documents.\", 'Follow-up will continue for chronic or recurrent GI symptoms persisting after 6 months until', 'symptoms resolve or stabilize.', '5.6 Loss to Follow-Up', 'Every reasonable effort must be made to contact any subject apparently lost to follow-up', 'during the study to complete study-related assessments and record outstanding data. After', 'unsuccessful telephone contact, the following is to occur:', 'Attempt to contact the subject by mail using a method that provides proof of receipt.', 'Try alternate contacts if permitted (eg, primary care providers, referring physician,', 'relatives).', \"Document the efforts in the subject's source documents.\", 'If all efforts fail to establish contact, the subject will be considered lost to follow-up.', '6', 'INVESTIGATIONAL PRODUCT INFORMATION', '6.1', 'General Information', 'The study treatments include AR101 and standard of care. Standard of care includes', 'avoidance of peanuts/peanut-containing foods, and education on recognition and', 'management of allergy symptoms and appropriate use of rescue medications (eg, epinephrine', 'auto-injectors).', 'The sponsor will provide AR101 capsules and sachets.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 41 of 122', '6.2 AR101 Product Characteristics', 'The AR101 active pharmaceutical ingredient is initially sourced as raw peanuts, Arachis', 'hypogaea, and is processed into food-grade, 12% defatted, roasted peanut flour that contains', 'approximately 50% peanut protein (wt/wt). The peanut flour, which contains peanut', 'allergens, is characterized for its relative composition of key allergenic proteins', '(Porterfield, 2009) by reversed-phase high performance liquid chromatography (HPLC) and', 'is tested for potency (relative to a reference standard) using an enzyme-linked', 'immunosorbent assay (ELISA) to demonstrate consistency between lots. The AR101 drug', 'product consists of the peanut flour formulated with bulking and flow agents in graduated', 'doses. The drug product is encapsulated in hydroxypropyl methyl cellulose (HPMC) or filled', 'in foil-laminate sachets and supplied in color-coded pull-apart capsules at 5 dosage strengths', '(0.5, 1, 10, 20, and 100 mg) and 300 mg sachets.', 'Additional details will be provided in the AR101 investigator brochure and pharmacy', 'manual.', '6.2.1', 'Packaging of AR101', 'Capsules containing study product are packaged in blister cards that are assembled into', 'dosing kits. Each individual blister of a blister card contains a dose for a single day. Each', 'dosing kit supplies 2 weeks of daily dosing for a single dose level plus another 7 days of', 'daily dosing at the same dose level to accommodate potential visit scheduling issues and', 'wasted or lost product.', 'Foil-laminate sachets for maintenance dosing are packaged in paperboard cartons for storage', 'and dispensing to study subjects.', 'The label will vary depending on individual country requirements.', '6.2.2', 'Storage of AR101', 'The study product should be stored in accordance with the product label and in a secure', 'location at 2\u00b0C to 8\u00b0C. Temperature excursions may be allowed with specific instructions', 'from Aimmune. Study sites will maintain temperature logs for all refrigerators used to store', 'study product during the study.', '6.2.3 Directions for Administration of AR101', 'The first dose at each dose level will be removed from the dosing kit for the assigned dose', 'level and administered under medical supervision at the study site. Once a dose is removed', 'from the dosing kit, the kit must be dispensed to the subject, held at the study site for', 'destruction, or returned to the sponsor designee according to the procedures in the pharmacy', 'manual. Once opened, dosing kits cannot be used for any other dosing interval or any other', 'subject. Subjects will be instructed to store the dosing kit in the refrigerator and return', 'unused study product to the study site at the next visit.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 42 of 122', 'Dosing Precautions', 'The subject must have other food (besides the matrix vehicle used to prepare the', 'dose) in the stomach before taking the dose. The daily dose at home should be taken', 'as part of a meal or heavy snack except on days the dose is given at the study site (the', 'subject should not have an empty stomach).', 'Subjects are to avoid activities likely to increase allergic reactivity (eg, exercising or', 'taking hot showers or baths) within 3 hours after dosing.', 'For subjects engaging in strenuous exercise before the planned dosing time, dosing', 'should be delayed until any signs of a hypermetabolic state (eg, flushing, sweating,', 'rapid breathing, and/or rapid heart rate) have abated.', 'Dosing should not occur within 2 hours before bedtime.', 'In case of illness or symptoms such as wheezing, worsening asthma, fever, vomiting,', 'or diarrhea, the subject or parent/caregiver is to withhold the dose of study product', 'and notify the study site of the symptoms and for possible dose adjustments.', 'Dose Preparation', 'The same procedures will be followed for preparing and administering study product at the', 'study site or at home. Study site doses may be prepared by site staff, the subject, or the', 'parent/caregiver under direct supervision of study site staff for training purposes. Doses at', 'home will be prepared by the subject or supervising adult using a vehicle food', '(eg, applesauce, yogurt, pudding, or other age-appropriate semisolid matrix food) to which', 'the subject is not allergic. The vehicle food volume should be appropriate so the entire dose', 'can be consumed in a few spoonfuls/mouthfuls in one sitting. The vehicle food must not be', 'heated above room temperature before adding the study product or consumption.', 'Capsules constituting the dose should be pulled apart, gently rolled between the finger and', 'thumb over the vehicle food, and then lightly tapped at the end of each half of the capsule to', 'ensure full delivery of the study product. When using a sachet packet, the packet is to be cut', 'over the vehicle food and the entire contents emptied into the food. The sachet should then', 'be gently squeezed and shaken to ensure full delivery of the study product. Subjects should', 'avoid inhaling the study product, which may induce an allergic reaction or worsening of', 'asthma. The study product should be mixed thoroughly with the vehicle food before', 'administration.', 'Dose Timing', 'The study product should be consumed as promptly as possible after mixing. If not', 'consumed within 4 hours after mixing into a vehicle, the mixture should be discarded and', 'a new dose prepared. If preparing a new dose is not feasible (eg, due to limited supply), the', 'study product-vehicle food mixture may be stored for up to 24 hours under conditions', 'appropriate for the vehicle food matrix. If consumption is delayed more than 24 hours, the', 'mixture must be discarded and a new dose mixed and consumed.']", "completion": ""}